Central Skull Base Osteomyelitis: 10-Case Series in a Single Center.
10.3342/kjorl-hns.2016.59.3.207
- Author:
Byung Kil KIM
1
;
Woori PARK
;
Nayeon CHOI
;
Gwanghui RYU
;
Hyo Yeol KIM
;
Hun Jong DHONG
;
Seung Kyu CHUNG
;
Sang Duk HONG
Author Information
1. Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. kkam97@gmail.com
- Publication Type:Original Article
- Keywords:
Central skull base osteomyelitis;
Cranial nerve palsy;
Malignant otitis externa;
Skull base tumor
- MeSH:
Anti-Bacterial Agents;
Biopsy;
Blood Sedimentation;
Cardiovascular Diseases;
Cranial Nerve Diseases;
Debridement;
Diabetes Mellitus;
Diagnosis;
Female;
Follow-Up Studies;
Headache;
Humans;
Immunosuppression;
Liver Transplantation;
Male;
Medical Records;
Mortality;
Neurologic Manifestations;
Occipital Bone;
Osteomyelitis*;
Otitis Externa;
Retrospective Studies;
Skull Base*;
Skull*;
Temporal Bone
- From:Korean Journal of Otolaryngology - Head and Neck Surgery
2016;59(3):207-213
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND AND OBJECTIVES: Skull base osteomyelitis (SBO) typically evolves as a complication of malignant otitis externa (MOE) in diabetic patients and involves the temporal bone. Central SBO (CSBO), which mainly involves the sphenoid or occipital bones, has clinicaland radiological characteristics similar to those of SBO but without coexisting MOE. We investigated a group of patients with CSBO and studied the clinical course of CSBO. SUBJECTS AND METHOD: Medical records of patients who were diagnosed with CSBO were retrospectively analyzed from 1999 to 2014. RESULTS: Ten patients (mean age; 60.5 years) were identified. There were five males and five females. All patients suffered from headache, and six patients had cranial nerve palsy including oculomotor (20%), abducens (10%), vestibulocochlear (10%), glossopharyngeal (20%), vagus (30%) and hypoglossal (10%) nerve. Patients had underlying diseases including diabetes mellitus (40%), immunosuppression status after liver transplantation (10%) and cardiovascular disease (40%). Four patients received endoscopic biopsy and debridement for diagnostic and curative intent. Patients were treated with intravenous antibiotics for 5.1 weeks in average and oral antibiotics for 17 weeks. Mean follow-up period was 12.4 months and the mortality rate was zero. 40% of patients had residual neurologic deficit. The earliest sign of improving CSBO was headache (mean; 3.1 weeks) and the erythrocyte sedimentation rate was the latest improving sign (mean; 4 months). CONCLUSION: CSBO was diagnostic and therapeutic challenge to the clinicians. The timely diagnosis and long-term antibiotics therapy could avoid a mortality case and minimize the permanent neurologic deficit.
